본문 바로가기

Prognostic Role of TMED3 in Clear Cell Renal Cell Carcinoma: A Retrospective Multi-Cohort Analysis

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q2Scopus Q2
저널
FRONTIERS IN GENETICS10 · 2019
피인용
Web of Science 27Scopus 26
FWCI (Scopus)
1.37
JCR IF
JCR 2018 3.517
ISSN
1664-8021

저자

  1. 하미향제1저자Department of Anatomy, School of Medicine, Pusan National University, Yangsan, South Korea
  2. 문환Department of Premedicine, School of Medicine, Pusan National University, Yangsan, South Korea
  3. Choi, DongwookDivision of Drug Process Development, New Drug Development Center, Osong Medical Innovation Foundation, Cheongju, South Korea
  4. Kang, WonmoDivision of Drug Process Development, New Drug Development Center, Osong Medical Innovation Foundation, Cheongju, South Korea
  5. Kim, Ji-HongDivision of Drug Process Development, New Drug Development Center, Osong Medical Innovation Foundation, Cheongju, South Korea
  6. Lee, Keon JinDivision of Drug Process Development, New Drug Development Center, Osong Medical Innovation Foundation, Cheongju, South Korea
  7. Park, DongsuDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, United States
  8. 강치덕Department of Biochemistry, Pusan National University School of Medicine, Yangsan, South Korea
  9. 오세옥Department of Anatomy, School of Medicine, Pusan National University, Yangsan, South Korea
  10. 한명은Department of Anatomy, School of Medicine, Pusan National University, Yangsan, South Korea
  11. 김윤학교신저자Department of Anatomy, Biomedical Research Institute, School of Medicine, Pusan National University, Yangsan, South Korea
  12. 이동준Department of Convergence Medical Science, Pusan National University School of Medicine, Yangsan, South Korea

초록

Transmembrane p24 trafficking protein 3 (TMED3) is a metastatic suppressor in colon cancer and hepatocellular carcinoma. However, its function in the progression of clear cell renal cell carcinoma (ccRCC) is unknown. Here, we report that TMED3 could be a new prognostic marker for ccRCC. Patient data were extracted from cohorts in the Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC). Differential expression of TMED3 was observed between the low stage (Stage I and II) and high stage (Stage III and IV) patients in the TOGA and ICGC cohorts and between the low grade (Grade I and II) and high grade (Grade III and IV) patients in the TOGA cohort. Further, we evaluated TMED3 expression as a prognostic gene using Kaplan-Meier survival analysis, multivariate analysis, the time-dependent area under the curve (AUC) of Uno's C-index, and the AUC of the receiver operating characteristics at 5 years. The Kaplan-Meier analysis revealed that TMED3 overexpression was associated with poor prognosis for ccRCC patients. Analysis of the C-indices and area under the receiver operating characteristic curve further supported this. Multivariate analysis confirmed the prognostic significance of TMED3 expression levels (P = 0.005 and 0.006 for TOGA and ICGC, respectively). Taken together, these findings demonstrate that TMED3 is a potential prognostic factor for ccRCC.

키워드

TMED3TCGAICGCclear cell renal cell carcinomaprognosisP24 PROTEINSCANCERIDENTIFICATIONTRAFFICKINGPATHOLOGYGENOMICSNETWORKTLR4

식별자

Scopus EID
2-s2.0-85067917668
WoS UID
000465102900001